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croscopy revealed a co-localization of ochronotic pigment and SAA-
amyloid, tissue calciﬁcation, lipid oxidation, inﬂammation, and tissue
degeneration.
Alkaptonuric specimen was obtained from a patient (Table 1) who
underwent biologic aortic valve replacement. AKU patient had been
previously diagnosed for secondary amyloidosis as SAA-amyloid had
been detected in her cartilage and synovia [8]. Echocardiogram revealed
severe aortic stenosis with an aortic transvalvular mean gradient of
53 mm Hg, a peak transvalvular gradient of 89, a peak of systolic veloc-
ity (m/s) of 4.7 and valve area of 0.82 cm2 and an AVA indexed for body
weight of 0.52 cm2. Inter-ventricular septal thickness was 12 mm. LeftAlkaptonuria (AKU) is an ultra-rare disease developed from the lack
of homogentisate 1,2-dioxygenase activity, causing an accumulation of
homogentisic acid (HGA) in pigmented deposits (ochronosis) in con-
nective tissues, especially in the joints and heart. AKU is mostly asymp-
tomatic in early life, with arthropathy and cardiovascular symptoms
appearing in later decades of life. Cardiovascular involvement has
been described in as many as 40% of AKU patients (mean and median
age of detection being 54 and 52 years, respectively) [1]. Alkaptonuric
ochronosis can be treated symptomatically during the early stages,
whereas for end stages total joint and heart valve replacements may
be required [1–3], but no speciﬁc cure exists at the moment, although
a phase II clinical trial with nitisinone is in progress.
Thanks to the use of our in vitro, cell and tissue AKUmodels [4–10],
we recently provided experimental evidence that AKU is a secondary
serum amyloid A (SAA)-based amyloidosis [8]. A co-localization of
ochronotic pigment and SAA-amyloid was also reported [8].
In the present work, using Congo Red (CR) birefringence and immu-
noﬂuorescence, we report for the ﬁrst time the presence of SAA-logie, Chimica e Farmacia, via
x: +39 0577234903.
).
land Ltd. Open access under CC BY-NCamyloidosis in the stenotic aortic valve of an AKU patient. Light mi-
ventricular systolic function was preserved. In view of the severe aortic
stenosis the patient underwent elective aortic valve replacement. The
postoperative course was uneventful and the patient recovered well
from surgery at one-year follow-up.
After surgery AKU aortic valve sections were stained with eosin/
hematoxylin, CR stained for amyloid detection or used for immunoﬂuo-
rescence staining with anti-SAA and anti-4-hydroxy-2-nonenal (4-HNE)
antibodies.
At a glance, the aortic valve revealed massive deposits of ochronotic
pigment with calciﬁcation in the cusps (Fig. 1A). Sclerotic change in the
cusps, and shrinkage of the non-coronary cusp, impeding normal coap-
tation of the aortic valve, associated with diffuse ochronotic deposition,
appeared to be the causative lesions of the need for aortic valve replace-
ment. Ochronosis was associated with areas of valvular calciﬁcation.
Lightmicroscopy examinations consistently showed severe calciﬁcation
involving surface endothelium (Fig. 1B). CR staining detected the pres-
ence of diffuse amyloid, mainly located in densely sclerotic and poorly
vascularised scar tissue and co-localization of amyloid and ochronotic
pigment was visible in close proximity to calciﬁc deposits (Fig. 1C).
Co-localization of SAA deposition with ochronotic pigmentation was
detected (Fig. 1D). Major products of lipid peroxidation (LPO) were
detected in AKU valve sections incubated with anti-4-HNE antibody
(Fig. 1E). LPO were perfectly superimposing to pigmented areas,
suggesting the association of intraleaﬂet ochronosis and oxidative stress
(Fig. 1E). AKU valve also contained macrophages in the subendothelial
layer of the ﬁbrosa, in the vicinity of ochronotic deposits, and along
the lamina elastic (Fig. 1B). An evident co-localization between oxidized
lipids, inﬂammation and ochronosis suggested that LPO might play a
role in the disease process.
Our present investigation conﬁrmed the hitherto unsuspected exis-
tence of AKU-linked secondary amyloidosis, involving also the cardiac-ND license. 
Table 1
Clinical history of the patient.
Sex year of birth Female 1948
1985 Meniscus break (L)
1986 3 lumbosciatica attacks Reduction in spinal discs Spondylolisthesis AKU diagnosis
1987 Low proteins diet: no results Tiroxina with C protein
1989 Meniscus break (R)
1994 Achilles' tendon thickening (L)
1997 Drooling Hiatus hernia Esophagitis (II degree)
1998 Ulna and radial head capitellum break (R)
2001 Knee rotuleus tendon break (L)
2003 Macroglossia
2005 Thyroid removal Hip prosthesis (R) with bone replacement
2006 Hip prosthesis (L)
2008 Tachycardia Aortic valve stenosis
2010 2 ribs break
2011 Aortic valve replacement
AKU features Elbows and heels bursitis Shoulder pain 15 cm decline of height Amyloid deposits in cartilage,
synovia and aortic valve
SAA plasma level 110 mg/L
SAP plasma level 50 μg/L
HGA plasma level 11 μg/mL
HGA urine excretion 8.6 g/day
HGD Mutation G270R
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yloidosis in the heart.
The striking co-localization of pigment and amyloid suggested that
HGA might be involved in amyloid deposition in the heart.
In conclusion, the emerging view in this AKU case is that valve calci-
ﬁcation represents a meeting of lipid oxidation with chronic inﬂamma-
tion and amyloid deposition. In AKU cases, surgical replacement of
aortic valves results in signiﬁcant improvement. Physicians and sur-
geons should be aware of multiple system involvement in this disorder,
as early recognition and appropriate treatment may signiﬁcantly im-
prove the quality of life in AKU patients.
Acknowledgments
Thiswork has been supported by TELETHON ITALY grant GGP10058.
The authors thank the alkaptonuric patientwho generously donated
her aortic valve for the present study, AimAKU (Associazione Italiana
Malati di Alcaptonuria, ORPHA263402), Toscana Life Sciences Orphan_1
project and Fondazione Monte dei Paschi di Siena 2008–2010.References
[1] Thakur S, Markman P, Cullen H. Choice of valve prosthesis in a rare clinical condi-
tion: aortic stenosis due to alkaptonuria. Heart Lung Circ 2013;22(10):870–2.
[2] Hiroyoshi J, Saito A, Panthee N, et al. Aortic valve replacement for aortic stenosis
caused by alkaptonuria. Ann Thorac Surg 2013;95:1076–9.
[3] Lok ZS, Goldstein J, Smith JA. Alkaptonuria-associated aortic stenosis. J Card Surg
2013;28:417–20.
[4] Braconi D, Bernardini G, Bianchini C, et al. A biochemical and proteomic characteri-
zation of alkaptonuric chondrocytes. J Cell Physiol 2012;227:3333–43.
[5] Braconi D, Bianchini C, Bernardini G, et al. Redox-proteomics of the effects of
homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis.
J Inherit Metab Dis 2011;34:1163–76.
[6] BraconiD, LaschiM,Amato L, et al. Evaluation of anti-oxidant treatments in an in vitro
model of alkaptonuric ochronosis. Rheumatology (Oxford) 2010;49:1975–83.
[7] Braconi D, Laschi M, Taylor AM, et al. Proteomic and redox-proteomic evaluation of
homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell
Biochem 2010;111:922–32.
[8] Millucci L, Spreaﬁco A, Tinti L, et al. Alkaptonuria is a novel human secondary
amyloidogenic disease. Biochim Biophys Acta 1822;2012:1682–9.
[9] Tinti L, Spreaﬁco A, Braconi D, et al. Evaluation of antioxidant drugs for the treat-
ment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol
2010;225:84–91.
[10] Tinti L, Taylor AM, Santucci A, et al. Development of an in vitro model to investigate
joint ochronosis in alkaptonuria. Rheumatology (Oxford) 2011;50:271–7.
Fig. 1. A) Macroscopic aspect of AKU aortic valve showing a rough surface of the leaﬂets and ochronotic pigmentation on the surface. A thickening of the central areas of the cusps with
nodule-like structures is visible (arrow). B) Light microscopy (hematoxylin and eosin staining) examinations of AKU aortic valve with intense inﬂammatory cell inﬁltrate that includes
large cells macroscopically corresponding to macrophages (arrows). Magniﬁcation 20×. C) Congo Red staining of AKU aortic valve amyloid deposits. Left: unpolarized light. Valve tissue
was ever stained red (“congophilic”); Right: polarized light. The pigmented areas (arrows)were also birefringent, indicating overlapping of ochronosis and amyloid.Magniﬁcation 40×. D)
SAA was present in AKU aortic valve amyloid deposits. Positive staining for SAA-amyloid was particularly intense in correspondence of ochronotic pigmentation. Magniﬁcation 20×. E)
Immunoreactivity for 4-HNE in AKU aortic valve leaﬂet. The presence of 4-HNE in the AKU valve was uniformly diffused and the distribution of 4-HNE-positive area was perfectly
superimposing to ochronotic pigmented areas. The presence of lipid peroxidation and ochronotic pigment was found to be strictly related to areas of lymphocytes accumulation. Magni-
ﬁcation 20×.
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